Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSIMERTINIB MESYLATE vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that selectively inhibits EGFR exon 19 deletion and L858R substitution mutations, as well as T790M resistance mutations, with less activity against wild-type EGFR.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
FDA-approved: Adjuvant therapy after tumor resection in patients with EGFR exon 19 deletions or exon 21 L858R mutations; first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations; metastatic NSCLC with EGFR T790M mutation after progression on EGFR TKI therapy.,Off-label: Treatment of leptomeningeal carcinomatosis from EGFR-mutant NSCLC.
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
80 mg orally once daily, with or without food.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
Terminal elimination half-life is approximately 48 hours (range 36-60 h) based on population pharmacokinetic analysis, supporting once-daily dosing.
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Metabolized primarily by CYP3A4; minor contributions from CYP3A5 and CYP1A1. Forms active metabolites (AZ5104 and AZ7550) that contribute to clinical activity.
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Osimertinib is eliminated primarily via feces (67.8%, with 1.2% as unchanged drug) and urine (13.8%, with 0.8% as unchanged drug). The remainder is recovered as metabolites.
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
Approximately 95% bound to human plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
47% bound to human plasma proteins, primarily albumin.
Apparent volume of distribution (Vd/F) is approximately 956 L, suggesting extensive tissue distribution. Not expressed per kg, but corresponds to a very large Vd (approximately 13.7 L/kg for a 70 kg person).
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
Oral bioavailability is estimated to be approximately 70% based on mass balance and absorption studies. Absorption is unaffected by food.
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
No dose adjustment required for GFR >=15 m L/min; insufficient data for GFR <15 m L/min or dialysis.
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: 80 mg once daily; Child-Pugh C: not recommended due to lack of data.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Safety and efficacy not established in pediatric patients.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
No specific dose adjustment; clinical studies included patients >=65 years with no overall differences in safety or efficacy.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
Black Box Warning: Interstitial lung disease (ILD)/pneumonitis, which can be fatal. Monitor for new or worsening respiratory symptoms. Withhold or permanently discontinue based on severity.
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
Interstitial lung disease (ILD)/pneumonitis: Monitor pulmonary symptoms; withhold or permanently discontinue based on severity.,QTc interval prolongation: Monitor electrolytes and ECG in patients with risk factors; withhold or permanently discontinue for QTc >500 ms.,Cardiomyopathy: Assess left ventricular ejection fraction (LVEF) before and during treatment; withhold for symptomatic congestive heart failure.,Keratitis: Evaluate for signs of keratitis, especially in patients with prior ocular conditions.,Fetal harm: Can cause fetal harm; advise females of reproductive potential of effective contraception during and for 6 weeks after treatment.,Embryo-fetal toxicity: Verify pregnancy status before initiation.
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
None (no absolute contraindications listed in prescribing information).
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
Avoid grapefruit and grapefruit juice, Seville oranges, and star fruit due to potential CYP3A4 inhibition. No other dietary restrictions.
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
Based on its mechanism of action (EGFR tyrosine kinase inhibition) and animal studies, osimertinib is expected to cause fetal harm when administered to a pregnant woman. In animal reproduction studies, osimertinib was embryotoxic and teratogenic at exposures below the recommended human dose. First trimester exposure poses the highest risk for major malformations. Second and third trimester exposure may cause fetal growth retardation and oligohydramnios. Use is contraindicated in pregnancy unless no alternative therapy exists.
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
It is unknown whether osimertinib or its metabolites are excreted in human milk. However, due to the potential for serious adverse reactions in breastfed infants (e.g., EGFR inhibition affecting neonatal growth and development), breastfeeding is not recommended during treatment and for at least 3 weeks after the last dose. No human milk-to-plasma (M/P) ratio data are available.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
No specific dose adjustments for pregnancy have been established due to lack of human data. Pregnancy-induced changes in drug absorption, distribution, metabolism, and excretion (e.g., increased renal blood flow, altered CYP3A activity) may alter osimertinib exposure; however, therapeutic drug monitoring is not routinely recommended. The manufacturer advises avoiding use in pregnancy unless benefit outweighs risk; if used, consider monitoring for toxicity due to potential altered pharmacokinetics.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
Osimertinib is a third-generation EGFR-TKI selective for both sensitizing and T790M resistance mutations. Monitor for interstitial lung disease (ILD) and QTc prolongation. Dose reduction or interruption may be needed for adverse reactions. Avoid concurrent use with strong CYP3A4 inducers.
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
Take exactly as prescribed, once daily with or without food.,Avoid grapefruit, grapefruit juice, Seville oranges, and star fruit during treatment.,Report new or worsening respiratory symptoms (cough, dyspnea, fever) immediately.,Notify your doctor if you experience palpitations, dizziness, or fainting (QT prolongation risk).,Use effective contraception during treatment and for 6 weeks after the last dose.,Breastfeeding is not recommended while on this medication.
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
"Metronidazole is a known inhibitor of CYP3A4, the primary enzyme responsible for metabolizing Osimertinib. Coadministration increases Osimertinib AUC by approximately 30-60%, leading to elevated plasma concentrations that may potentiate adverse effects such as QTc prolongation, interstitial lung disease, and diarrhea. Clinicians should monitor for signs of Osimertinib toxicity and consider dose reduction if concurrent use is unavoidable."
"Osimertinib, a tyrosine kinase inhibitor used in non-small cell lung cancer, can inhibit P-glycoprotein (P-gp) transport in the gastrointestinal tract and kidneys, leading to increased absorption and reduced renal clearance of digoxin. This elevation in serum digoxin concentration heightens the risk of digoxin toxicity, including cardiac arrhythmias (e.g., bradycardia, atrial tachycardia with block) and gastrointestinal symptoms such as nausea and vomiting. Clinical monitoring for digoxin toxicity is warranted, especially when initiating or adjusting osimertinib therapy."
"Osimertinib, a potent EGFR tyrosine kinase inhibitor, significantly reduces the serum concentration of rasagiline, a monoamine oxidase B (MAO-B) inhibitor used in Parkinson's disease. This interaction is primarily mediated through Osimertinib's induction of CYP1A2, the major enzyme responsible for rasagiline metabolism, leading to enhanced clearance and subtherapeutic rasagiline levels. Clinically, this may result in reduced efficacy of rasagiline, potentially worsening Parkinsonian symptoms and requiring dose adjustments."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSIMERTINIB MESYLATE vs CLOLAR, answered by our medical review team.
OSIMERTINIB MESYLATE is a Antineoplastic Agent that works by Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that selectively inhibits EGFR exon 19 deletion and L858R substitution mutations, as well as T790M resistance mutations, with less activity against wild-type EGFR.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSIMERTINIB MESYLATE and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSIMERTINIB MESYLATE is: 80 mg orally once daily, with or without food.. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSIMERTINIB MESYLATE and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSIMERTINIB MESYLATE is classified as Category C. Based on its mechanism of action (EGFR tyrosine kinase inhibition) and animal studies, osimertinib is expected to cause fetal harm when administered to a pregnant woman. In animal . CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.